Simbec-Orion Group

Simbec-Orion Group

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $45M

Overview

Simbec-Orion Group is a long-established, mid-sized, and privately-held clinical research organization (CRO) headquartered in Cardiff, UK. It provides end-to-end clinical development services, distinguishing itself through a flexible, specialist approach and deep expertise in challenging therapeutic areas like rare diseases, oncology, CNS, and respiratory. The company operates globally, leveraging its own clinical pharmacology unit and central laboratory to offer integrated, full-service solutions to biopharma clients. Its business model is entirely service-based, generating revenue from contracted research and consulting work.

OncologyRare DiseasesCNSRespiratoryAddiction

Technology Platform

Integrated CRO service platform featuring an in-house Clinical Pharmacology unit for early-phase studies, a Central Laboratory for bioanalytical and safety testing, and expertise in advanced data analytics (e.g., AI causal modeling).

Funding History

2
Total raised:$45M
Series B$30M
Series A$15M

Opportunities

Strong growth in orphan drug and oncology R&D spending drives demand for CROs with specialized expertise.
The trend towards functional service outsourcing and integrated partnerships benefits full-service, mid-sized CROs that can offer strategic counsel and execution.
Expansion of decentralized trial capabilities and advanced data analytics presents avenues for service differentiation.

Risk Factors

Intense competition from both large global CROs and small niche players.
Revenue dependency on a limited client base and cyclical biopharma R&D budgets.
Operational risks related to trial execution quality, data security, and regulatory compliance.
High reliance on attracting and retaining specialized scientific and clinical talent.

Competitive Landscape

Operates in the highly competitive global CRO market, competing against large, full-service players (e.g., IQVIA, ICON) with greater scale and resources, as well as smaller, niche CROs. Differentiates through a mid-size, agile structure, deep therapeutic specialization in complex areas (rare diseases, oncology), and an integrated service model combining clinical operations with owned clinical pharmacology and central lab units.